Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced ...

Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in Alzheimer's & Dementia: Translational ...

Scientists are urgently seeking fluid biomarkers for frontotemporal dementia, the most common dementing illness among 40- and ...

G-CSF has been evaluated as an adjunct to standard ... these findings are limited by factors such as small sample sizes, selection bias, and lack of an appropriate control group.

Neonates were defined as aged 0 to <1 month and young infants as aged 1–3 month. For those infants who had >1 CSF sample collected, the parameters from the first CSF were used for analysis, unless a ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Long-term safety data with median follow-up of two years, and out to more than four years, demonstrate that tividenofusp alfa was generally well tolerated Regulatory submission for accelerated ...

Biosimilars Market Poised for Rapid Growth, Driven by Advancements in Therapeutics and Expanding Patient AccessPune, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Global Biosimilars Market Size & Growth Analysis: ...

Liquid Biopsy MarketThe global liquid biopsy market is poised for substantial expansion, with an estimated revenue of USD 1,538.3 million in 2023. The market is projected to grow at an impressive ...